Founder led companies can offer something many investors value in a world of shifting inflation data, mixed growth signals, and frequent policy surprises: leaders whose own reputations and long term vision are closely tied to shareholder outcomes. With global rates, energy costs, and consumer demand all pulling markets in different directions, backing founders who remain deeply invested in their business can be one way to focus on execution rather than headlines. This article highlights 3 stocks from a Founder Led Companies screener that aims to spotlight businesses where leadership and ownership are closely aligned with you as a shareholder.
Samsara (IOT)
Overview: Samsara is an IoT and software company that connects data from vehicles, equipment, and worksites into a single connected operations platform so customers can improve safety, efficiency, and asset tracking. Its tools combine hardware like cameras and sensors with AI driven software to help industries such as transportation, logistics, construction, and the public sector manage real time operations.
Operations: Samsara generates about US$1.73b in revenue almost entirely from Software & Programming, with around US$1.48b coming from the United States and about US$255.6m from other regions.
Market Cap: US$22.33b
Samsara gives investors direct exposure to the shift toward data driven physical operations, backed by a US$1.89b ARR base growing 30% year over year and a customer set that includes thousands of enterprises with net revenue retention above 115%. Recent profitability, with Q1 2026 net income of US$44.51m and positive earnings per share, indicates that its AI powered video safety, asset tracking, and automation products are delivering value in day to day operations. At the same time, a high P/S multiple and recent insider selling highlight the importance of closely monitoring execution and expectations. For investors who want to understand how this founder led platform compares in terms of growth, quality, and risks, the detailed breakdown provides additional context beyond the headline numbers.
Samsara’s 30% ARR growth, positive earnings, and rich P/S multiple suggest a story that many investors only half see; the real question is what the 2 key rewards and 1 important warning sign reveals about where expectations could crack or surprise.
China Medical System Holdings (SEHK:867)
Overview: China Medical System Holdings is a Hong Kong headquartered pharmaceutical group that focuses on manufacturing, marketing, and distributing specialist treatments in China across cardiovascular, gastroenterology, dermatology, eye care, and pain management.
Operations: China Medical System Holdings generates roughly CN¥7.17b from its Integrated Business and CN¥1.07b from its Skin Health Business, with virtually all of its CN¥8.21b in revenue coming from the PRC.
Market Cap: HK$29.46b
China Medical System Holdings provides exposure to a focused China pharma platform that combines a broad specialty portfolio with a developing pipeline, from new rabies and allergy biologics to ophthalmology and autoimmune candidates moving through trials and approvals. Analysts currently expect earnings and revenue growth, see meaningful upside to their fair value estimates, and the board has supported this view with a sizable share buyback and ongoing dividends, even as net margins have eased from 21.7% to 18.1% and future ROE is forecast at 8.2%. The key consideration is how its product rollout, funding structure, and valuation compare when weighing these forecasts against the company’s risk profile and balance sheet characteristics.
China Medical System Holdings is leaning on forecasts, dividends, and buybacks, yet softer margins and an 8.2% ROE outlook raise questions. For the fuller story, see the analysis report for China Medical System Holdings
GH Research (GHRS)
Overview: GH Research is a Dublin based clinical stage biopharmaceutical company developing psychedelic based treatments for hard to treat depression, led by its inhaled mebufotenin product GH001 for severe forms such as treatment resistant depression, bipolar II disorder and postpartum depression.
Market Cap: US$2.0b
GH Research sits at the intersection of psychedelics and mental health, an area that now has clearer FDA guidance and a planned public hearing that may ease regulatory overhang for companies in this space. Its GH001 program has produced encouraging Phase 2a postpartum depression data, including rapid symptom relief, no serious adverse events and early signs that treatment can be managed alongside breastfeeding, while GH002 adds a second route of administration in early testing. At the same time, GH Research is unprofitable, generates less than US$1m in revenue, carries a relatively high P/B multiple and funds itself through equity raises, including a recent US$117.5m follow on offering, as well as higher risk external borrowing. Investors comparing these scientific and policy tailwinds with continuing losses and funding needs may find the risk reward trade off particularly important for a founder led story like this.
GH Research sits where cutting edge depression science meets early stage balance sheet risk, and the 2 warning signs (1 is major!) could be the clue to how long the cash, trials, and sentiment really line up before the story changes.
The three founder led stocks in this article are just a starting point, and the full screener has flagged 1,451 more companies with leaders building legacies that could carry equally compelling narratives in the Founder-Led Companies screener. Use Simply Wall St to identify, filter, and analyze the specific catalysts and founder led stories that match your highest conviction ideas so you can focus on the leadership traits and ownership signals that matter most.
Take Control of Your Investment Journey
If Samsara or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Curious About Alternative Stock Paths?
Fresh ideas can move fast, and the stocks sitting quietly today often lead the next breakout before the crowd catches on. Scan these curated picks while it matters and consider your options with care.
- Target resilient price action by reviewing companies in the 82 resilient stocks with low risk scores that aim to keep portfolio swings contained while broader markets are rising or falling.
- Explore structural demand trends by checking the 33 power grid technology and infrastructure stocks packed with businesses tied to grid upgrades and electrical infrastructure momentum before they stop flying under the radar.
- Prepare for potential sector shifts by scanning the 33 elite gold producer stocks featuring producers that could be positioned at the center of the next move if capital rotates back into hard assets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com